Viatris and Biocon Biologics are in a position to launch their Abevmy (bevacizumab) biosimilar rival to Avastin in Europe after receiving a formal pan-European marketing authorization from the European Commission.
Earlier this year, the pair received positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use,...






